Literature DB >> 30693471

Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice.

B Y Yan1, B P Hibler1, T Menge1, L Dunn1, A L Ho1, A M Rossi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30693471      PMCID： PMC6486429          DOI： 10.1111/bjd.17692

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

1.  Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database.

Authors:  C William Hanke; Shivani K Mhatre; David Oliveri; Marko Zivkovic; Ivor Caro; Daniel Bergström; Keith Dawson; Camelia S Sima
Journal:  J Drugs Dermatol       Date:  2018-02-01       Impact factor: 2.114

2.  A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.

Authors:  Howard Sofen; Kenneth G Gross; Leonard H Goldberg; Harry Sharata; Tiffani K Hamilton; Barbara Egbert; Benjamin Lyons; Jeannie Hou; Ivor Caro
Journal:  J Am Acad Dermatol       Date:  2015-04-24       Impact factor: 11.527

Review 3.  Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.

Authors:  Audrey A Jacobsen; Adam S Aldahan; Olivia B Hughes; Vidhi V Shah; John Strasswimmer
Journal:  JAMA Dermatol       Date:  2016-07-01       Impact factor: 10.282

4.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Authors:  Aleksandar Sekulic; Michael R Migden; Nicole Basset-Seguin; Claus Garbe; Anja Gesierich; Christopher D Lao; Chris Miller; Laurent Mortier; Dedee F Murrell; Omid Hamid; Jorge F Quevedo; Jeannie Hou; Edward McKenna; Natalie Dimier; Sarah Williams; Dirk Schadendorf; Axel Hauschild
Journal:  BMC Cancer       Date:  2017-05-16       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.